WO1986002927A1 - 1,2,4-thiadiazole derivatives - Google Patents

1,2,4-thiadiazole derivatives Download PDF

Info

Publication number
WO1986002927A1
WO1986002927A1 PCT/JP1985/000617 JP8500617W WO8602927A1 WO 1986002927 A1 WO1986002927 A1 WO 1986002927A1 JP 8500617 W JP8500617 W JP 8500617W WO 8602927 A1 WO8602927 A1 WO 8602927A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
represented
halogen atom
alkyl
Prior art date
Application number
PCT/JP1985/000617
Other languages
French (fr)
Japanese (ja)
Inventor
Daigaku Takiguchi
Saburo Kano
Original Assignee
Nippon Soda Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Soda Co., Ltd. filed Critical Nippon Soda Co., Ltd.
Publication of WO1986002927A1 publication Critical patent/WO1986002927A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a novel 1,2,4-thiadiazole derivative having a bactericidal and protozoalicidal action against pathogenic microorganisms such as candidiasis, trichomoniasis, and dermatophytosis, and a method for producing the same.
  • pathogenic microorganisms such as candidiasis, trichomoniasis, and dermatophytosis
  • a compound similar to the compound of the present invention has the general formula
  • the present invention has the general formula
  • R represents a hydrogen atom, a halogen atom, 1-4 alkyl group, Application Benefits Full Affairs Lome butyl group, a phenyl group or a Ct ⁇ 4 ⁇ alkoxy group, '
  • n 0, 1 or 2;
  • A is a group represented by the formula Q , a group represented by the formula, or a group represented by the formula:
  • X is optionally substituted with a halogen atom or a halogen atom ( ⁇ 1-4 alkyl group, m is 0, 1 or 2,
  • B represents CH, N or N
  • r 3, r 4, r 5, r 6, r 7 and r 8 each represent a hydrogen atom, human Dorokishi group or C t ⁇ 4 alkyl groups k and j Waso respectively! : Indicates 2 or 3.
  • Q is a group represented by Formula 1,
  • r 9 may be substituted with a halogen atom, a 4- anolealkyl group, a C 1-4 alkoxy group,
  • E and D represent CH, N or N, respectively (however, E and D
  • D is not simultaneously N or N.
  • r 1 and iota ⁇ 2 are each a hydrogen atom, a halogen atom or an-alkyl group Y represents a 0, CH 2, S or S0 2.
  • Hal represents a halogen atom
  • represents 1 or 2
  • the condensation reaction between the compound represented by the general formula ( ⁇ ) and the compound represented by the general formula ( ⁇ ) is performed in the presence of a base in a solvent.
  • -Between 20'C and 150 preferably between 10'c and 80'c for 10 minutes to several roars.
  • Examples of the base to be used include alkali metal hydroxides such as sodium hydroxide and sodium hydroxide, sodium hydride, alkali metal hydrides such as hydrogenation sodium, and the like.
  • Usual bases such as alcoholic alcohols such as sodium methylate and tertiary amines such as triethylamine can be mentioned.
  • the solvent used depends on the type of base, such as ice, alcohols, benzene, tonolenene, xylene, DMF, DMSO, ether, THF, dioxane and HMPA. Solvents can be used.
  • organic peracids such as perbenzoic acid and hydrogen peroxide can be used.
  • the reaction is carried out in a solvent when synthesizing a compound of the general formula [I] wherein T1 is 1 in a solvent.
  • the reaction is performed with 1.2 equivalents or less of the compound represented by
  • n 1 or 2 '
  • the solvent used depends on the type of oxidizing agent, such as water, organic acids such as acetic acid, and ketones such as clog form, methylene chloride, and acetate. And the like are appropriately selected.
  • the desired product can be obtained by performing ordinary post-treatment.
  • T represents an alkali metal atom.
  • the compound in the general formula [I], can also be produced according to the following reaction formula depending on the type of the substituent represented by ⁇ .
  • the structure of the compound obtained in this way was determined from the results of analysis of IR, NMR, MASS, spectrum, and the like.
  • the benzene layer was washed with water, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and 5-[4-1 (phenoxy) phenylthio]-1,2, 4-thiadiazole 4.0 g (14 mmol, Yield 94%).
  • To 4.0 g (14 mmol) of the obtained compound was added 50 mL of a form of black mouth and 9.lg (37 mmol) of 70% methanol perbenzoic acid, and the mixture was heated and refluxed for 4 hours.
  • the black hole form layer was separated, washed twice with cold water, dried over anhydrous magnesium sulfate, and the black hole form was distilled off under reduced pressure.
  • 3 Dachiru 5 — [4 — (4-Trifluoromethyl benzene) benzenesulfonyl] 1, 1, 2, 4 — 3.8 g of thiadiazole crystals were obtained. This was recrystallized from cyclohexane to obtain a purified product. Melting point 80.5-81.5, TLC; silica gel-benzene single spot, H 1 —NMR; 52
  • Example 2 7.0 g (22 mmol) of the compound obtained in Example 1 was dissolved in 30 m of 1,2-dichloropentane, and 7 g of 25% fuming sulfuric acid was added thereto at 0 ° C with stirring for 0 min. . It was kept on ice for 1 hour, then heated and kept at 15'c for 1 hour. After distilling off 1,2-dichloroethane under reduced pressure, 40 g of ice was added to the obtained tar-like substance, followed by stirring and filtration to obtain a clear aqueous solution. This was cooled on ice and neutralized with a 20% aqueous sodium hydroxide solution. Crystals of sodium salt were deposited.
  • 1,4 g of 4'-methyl biphenyl 4 -thiol was dissolved in 30 m of ethanol, cooled to 110 ° C, and 1.4 g of 28% sodium methoxide was added. To this was added dropwise 1.3 g of 5-bromo-1,2,4-thiadiazole in 10 m of ethanol. After completion of the dropwise addition, the mixture was stirred at room temperature for 1 hour, and further heated under reflux for 10 minutes.
  • Table 1 shows typical examples of the compounds of the present invention produced in the same manner.
  • the compounds of the present invention are effective against pathogenic microorganisms such as candidiasis, trichomoniasis, dermatophytosis, etc., and exhibit an antibacterial activity superior to known compounds, particularly against candidiasis, and Skin No primary irritation is expected, and development as an antifungal agent is expected.
  • the antibacterial activity was measured by the agar plate dilution method using a microplate.
  • the test compound was dissolved in DMS0 to prepare a 100-fold solution of the final test concentration, and the mixture was added to the Sabrobe dextrose agar medium heated at 50 to 1: 100 and stirred well.
  • m to My Plate [Fa Icon 3047
  • Candida albicans IFO 0579 as a test bacterium, the antibacterial activity was measured by an agar plate dilution method using microplates. That is, the test compound was dissolved in DMS0 to prepare a 100-fold solution of the final test concentration, and the mixture was added to a Sabouraud glucose agar medium heated to 50% in a ratio of 1: 100, and the mixture was stirred well. Then, 1 m of the microplate was used for microplate [Falcon 3047 (registered trademark)].
  • the compounds were applied to Polyethylene glycol ointment (400 60% and 1540 40%) at 1% and 5 10%, applied to New Zealand white heron shaved skin, Draze, JH (J. pharm. Exp. Therap. 82, 377-390, 1944) to determine the primary stimulus rate (PII).
  • PII primary stimulus rate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds represented by formula (I), wherein R represents hydrogen, halogen, C1-4 alkyl, trifluoromethyl, phenyl or C1-4 alkoxy, n represents 0,1 or 2, A represents formula (II), wherein X represents halogen or optionally halogen-substituted C1-4 alkyl, m represents 0,1 or 2, B represents CH, N or (III), W represents -O-, formula (IV) wherein r3, r4, r5, r6, r7, and r8 each represents hydrogen, hydroxy or C1-4 alkyl, k and j each represents 1, 2, or 3, l represents 0 or 1, Q represents aryl such as substituted phenyl, substituted pyridyl, etc., E and D each represents CH, N or formula (III) (provided that E and D do not represent N or formula (III) at the same time), and r1 and r2 each represents hydrogen, halogen or C1-4 alkyl, and Y represents O, CH2, S or SO2, provided that symbols $(1,5)$ between positions 1 and 2 and between positions 3 and 4 in the Y-containing tricyclic system each represents a single or double bond have antifungal and antiprotozoan effects against candasis, trichomoniasis, mycosis, etc.

Description

明 細 書  Specification
。 1,2, 4—チア ジアゾ一ル誘導体 技術の分野 :  . 1,2,4-thiadiazol derivative Technical field:
本発明はカ ンジダ症、 ト リ コ モナス症、 皮虜糸状菌症 等の病原微生物に対し殺菌 · 殺原虫作用を有する新規な 1,2, 4 -チアジアゾール誘導体及びその製造方法に関す る。 背景技術  The present invention relates to a novel 1,2,4-thiadiazole derivative having a bactericidal and protozoalicidal action against pathogenic microorganisms such as candidiasis, trichomoniasis, and dermatophytosis, and a method for producing the same. Background art
本発明化合物に類似の化合物として一般式
Figure imgf000003_0001
A compound similar to the compound of the present invention has the general formula
Figure imgf000003_0001
(式中、 r は水素原子、 塩素原子、 メ チル基又はメ ト キ シ基.を示す。 ) で表される化合物が殺菌作用を有する ことは公知である。 〔特公昭 37-Π997 、 特公昭 38— 25 382 、 薬学雑誌 88巻、 1437〜49 (1968年) 等〕  (In the formula, r represents a hydrogen atom, a chlorine atom, a methyl group or a methoxy group.) It is known that the compound represented by the formula has a bactericidal action. [Japanese Patent Publication No. 37-Π997, Japanese Patent Publication No. 38-25382, Pharmaceutical Magazine 88, 1437-49 (1968), etc.]
しかしながらこれら公知の化合物は皮 If一次刺激性が 認められ、 殺菌剤として実用化することはできなかった, さ らにこ の皮虜一次刺激性が改善された化合物として 式 :However, these known compounds showed primary irritation to the skin, and could not be put to practical use as a fungicide. Formula:
Figure imgf000004_0001
〇〉 - CF3 で表される化合物 が提案されだ (特開昭 51 - 61370)がやはり実用化にはい たらなかった。 ― 発明の開示 :
Figure imgf000004_0001
〇〉-A compound represented by CF 3 has been proposed (JP-A-51-61370), but has not yet been put into practical use. -Disclosure of invention:
本発明は一般式  The present invention has the general formula
R  R
N -S(0)n 一 A C I  N -S (0) n one A C I
 ,
{式中、 Rは水素原子、 ハロゲン原子、 〜4 アルキ ル基、 ト リ フル务ロメ チル基、 フエニル基又は Ct〜4 ァ ルコキシ基を、 ' {Wherein, R represents a hydrogen atom, a halogen atom, 1-4 alkyl group, Application Benefits Full Affairs Lome butyl group, a phenyl group or a Ct~ 4 § alkoxy group, '
nは、 0、 1 又は 2を、  n is 0, 1 or 2;
Aは、 式 Q で表される基、 式 表される基、 又は 式 で表される基を、
Figure imgf000004_0002
A is a group represented by the formula Q , a group represented by the formula, or a group represented by the formula:
Figure imgf000004_0002
〔式中、 Xは、 ハロゲン原子又はハロゲン原子で置換さ れていてもよい (^〜4 アルキル基を、 mは、 0、 1又は 2を、 Wherein, X is optionally substituted with a halogen atom or a halogen atom (^ 1-4 alkyl group, m is 0, 1 or 2,
O  O
 †
Bは、 CH、 N又は Nを、  B represents CH, N or N,
Wは、 〇 N ■ C W is 〇 N ■ C
k r8 O kr 8 O
I II  I II
— o ~~ e 又は N— C を、  — O ~~ e or N— C
〔式中、 r3、 r4、 r5、 r6、 r 7及び r 8はそれぞれ水素原 子、 ヒ ドロキシ基又は C t4 アルキル基を k及び j はそ れぞれ!:、 2又は 3を示す。 ) Wherein, r 3, r 4, r 5, r 6, r 7 and r 8 each represent a hydrogen atom, human Dorokishi group or C t ~ 4 alkyl groups k and j Waso respectively! : Indicates 2 or 3. )
は 0又は 1 を、 OCH (r9)i Represents 0 or 1 and OCH (r 9 ) i
Qは式 一 で表される基、 Q is a group represented by Formula 1,
^-G 0  ^ -G 0
(式中、 Gは CH、 N又は Nを、 (Where G is CH, N or N,
r9はハロゲン原子で置換されていてもよい 〜4 ァノレキル基、 C 1〜 4 アルコキシ基、 r 9 may be substituted with a halogen atom, a 4- anolealkyl group, a C 1-4 alkoxy group,
1 0  Ten
式 S02N < (r10 及び r11 はそれぞれ水素 原子又は 〜 4 アルキル基を示す。 ) で表され る基、 式— S03M (M : ア ルカ リ金属) で表され る基、 ハロゲン原子又はニ ト ロ基を、 i は 0、 1又は 2を示す。 ) 式 で表される基Wherein S0 2 N <(r 10 and r 11 represents a hydrogen atom or 1-4 alkyl group.) In the depicted Ru group of the formula - S0 3 M (M: A Luke Li metal) in represented Ru group, halogen Atom or nitro group, i represents 0, 1 or 2. ) Group represented by the formula
Figure imgf000006_0001
Figure imgf000006_0001
式 (CH 2 ) h で表される基、 A group represented by the formula (CH 2 ) h,
(式中、 hは 3、 4又は 5を示す。 )  (In the formula, h represents 3, 4 or 5.)
C 3 - 8シク 口 アルキル基又は C 3 - 8 consequent opening alkyl or
式 N で表される基を
Figure imgf000006_0002
A group represented by the formula N
Figure imgf000006_0002
(式中、 B、 n及び Rは前記と同じ意味を示す。 )  (In the formula, B, n and R have the same meanings as described above.)
0  0
T  T
E及び Dはそれぞれ CH、 N又は Nを、 (但し、 E及び  E and D represent CH, N or N, respectively (however, E and D
0 .  0.
Dは同時に N又は Nではない。 ) D is not simultaneously N or N. )
r 1及び ι· 2はそれぞれ水素原子、 ハロゲン原子又は 〜 アルキル基を Yは、 0、 CH 2 、 S又は S02 を示す。 r 1 and iota · 2 are each a hydrogen atom, a halogen atom or an-alkyl group Y represents a 0, CH 2, S or S0 2.
但し、 Yを含む 3環系において 1 と 2及び 3 と 4 との間 の はそれぞれ 1重結合又は 2重結合を示す。 〕 } で表 される化合物及びその製造方法である。 However, between 1 and 2 and between 3 and 4 in the three-ring system containing Y represents a single bond or a double bond, respectively. ] And a method for producing the same.
発明を実施するための最良の形態 : BEST MODE FOR CARRYING OUT THE INVENTION
(1) 本発明は下記反応式に従って製造することができ る。 R 塩 基
Figure imgf000007_0001
(1) The present invention can be produced according to the following reaction formula. R base
Figure imgf000007_0001
〔 Π〕 〔 I〕 酸化剤 [Π] [I] Oxidizing agent
Figure imgf000007_0002
Figure imgf000007_0002
R NR N
N S (0)n " - A N S (0) n "-A
、S,  , S,
C I 〕  C I]
(式中、 Halはハロゲン原子、 η は 1 又は 2を示す, 一般式 〔 Π〕 で表される化合物と一般式 〔·ΠΙ〕 で表さ れる化合物との縮合反応は溶媒中 塩基の存在下 - 20 'C 〜 150で、 好ま じ く は— 10'c〜80'cの間で 10分から数哮 間行う。  (In the formula, Hal represents a halogen atom, η represents 1 or 2, and the condensation reaction between the compound represented by the general formula (Π) and the compound represented by the general formula (ΠΙ) is performed in the presence of a base in a solvent. -Between 20'C and 150, preferably between 10'c and 80'c for 10 minutes to several roars.
用いられる塩基としては水酸化ナ ト リ ゥム、 水酸化力 リ ウム等のアルカ リ金属水酸化物、 水素化ナ ト リ ウム、 水素化力 リ ゥム等のアル力 リ金属の水素化物、 ソ ジゥム メ チラー ト等のアルカ リ金属のアルコ ラ一 ト、 ト リ ェチ ルァ ミ ン等の 3級ア ミ ン等通常の塩基が挙げられる。  Examples of the base to be used include alkali metal hydroxides such as sodium hydroxide and sodium hydroxide, sodium hydride, alkali metal hydrides such as hydrogenation sodium, and the like. Usual bases such as alcoholic alcohols such as sodium methylate and tertiary amines such as triethylamine can be mentioned.
用いる溶媒は塩基の種類に応じて、 氷、 アルコール類 ベンゼン、 トノレエ ン、 キ シレン、 D M F、 D M S O、 ェ 一テル、 T H F、 ジォキサン、 H M P A等通常の不活性 溶媒が使用できる。 The solvent used depends on the type of base, such as ice, alcohols, benzene, tonolenene, xylene, DMF, DMSO, ether, THF, dioxane and HMPA. Solvents can be used.
一般式 〔 I 〕 ' で表される化合物を必要に応じて酸化 することにより一般式 〔 Π〕 〃 で表される化合物即ち一 般式 〔 I 〕 において nが 1 又は 2 の化合物が得られる。  By oxidizing the compound represented by the general formula [I] ′ as necessary, a compound represented by the general formula [Π] 〃, that is, a compound represented by the general formula [I], wherein n is 1 or 2 is obtained.
酸化剤としては過安息香酸等の有機過酸類や過酸化水 素等が使用できる。 反応は一般式 〔 I 〕 において T1が 1 の化合物を合成する場合は溶媒中、 — 20 'c〜20 'c好ま し く は 0 'C以下で酸化剤のモル数は一般式 〔 I 〕 ' で表さ れる化合物に対し、 1. 2当量以下で行う。  As the oxidizing agent, organic peracids such as perbenzoic acid and hydrogen peroxide can be used. The reaction is carried out in a solvent when synthesizing a compound of the general formula [I] wherein T1 is 1 in a solvent. The reaction is performed with 1.2 equivalents or less of the compound represented by
一般式 〔 I 〕 において nが 2の化合物を合成する場合 には酸化剤を一般式 〔 I 〕 ' で表される化合物に対し、 21当量以上使用し、 —20で〜 120 'cの間で反応を行う。 使用する溶媒は nが 1 の場合も 2 の'場合も酸化剤の種 類に応じて水、 酢酸等の有機酸、 ク ロ 口ホルム、 塩化メ チ レ ン、 ァセ ト ン等のケ ト ン類等を適宜選択する。 'The compound represented by, 2 1 using equivalent or more, to 120 at -20' formula (I) the oxidizing agent when n is combining two compounds in the general formula (I) between the c To carry out the reaction. When n is 1 or 2 ', the solvent used depends on the type of oxidizing agent, such as water, organic acids such as acetic acid, and ketones such as clog form, methylene chloride, and acetate. And the like are appropriately selected.
反応終了後は通常の後処理を行う こ とによつて目的物 を得る-ことができる。  After completion of the reaction, the desired product can be obtained by performing ordinary post-treatment.
(2) 一般式 〔 I 〕 において riが 2である化合物は下記 の反応式に従って直接製造することもできる。 (2) The compound of the general formula [I] wherein ri is 2 can also be directly produced according to the following reaction formula.
+ T02S一 A+ T0 2 S-A
Figure imgf000009_0001
Figure imgf000009_0001
C Π〕  C Π]
R
Figure imgf000009_0002
R
Figure imgf000009_0002
〔 I Γ'  [I Γ '
(式中、 Tはアルカ リ金属原子を示す。 )  (In the formula, T represents an alkali metal atom.)
(3) 一般式 〔 I 〕 において Αの置換基の種類によって は下記の反応式に従っても製造することができる。  (3) In the general formula [I], the compound can also be produced according to the following reaction formula depending on the type of the substituent represented by Α.
r10 r 10
(a) r9 が式— S02N< 又は式 S03Mで表される基の 場合: , When the groups represented by S0 2 N <or formula S0 3 M - (a) r 9 has the formula:,
Figure imgf000009_0003
Figure imgf000009_0003
~- N Xm , ((r "卜,  ~-N Xm, ((r "
N ~· S(0) 一 S0ZC £N ~ S (0) one S0 Z C £
、 B
Figure imgf000009_0004
(b) r9が二 ト口基の場合 :
, B
Figure imgf000009_0004
(b) When r 9 is a nitro group:
Figure imgf000010_0001
Figure imgf000010_0001
こう して得られた化合物の構造は I R、 N M R、 M A S S 、 スぺク ト ル等の分折結果から決定した。 The structure of the compound obtained in this way was determined from the results of analysis of IR, NMR, MASS, spectrum, and the like.
次に実施例を挙げ本発明を更に詳細に説明する。  Next, the present invention will be described in more detail by way of examples.
実施例 1 化合物番号 89
Figure imgf000010_0002
Example 1 Compound No. 89
Figure imgf000010_0002
Figure imgf000010_0003
Figure imgf000010_0003
エタノ ール 20 m を氷冷し、 攪拌下これに 28%ナ ト リ ゥムメ チラー トメ タ ノ ール液 2.9g (15ミ ノレモノレ) 、 4 一 (フエノ キシ) チオフ ノ ール 3.0g (14.8ミ ルモル) お よび 5 —ブロム— 1 , 2 , ーチアジアゾール 2.5g ( 15ミ ル モル) を加え氷冷下に 30分保つた後 50'c に 2時間保つた 反応物を漶縮乾固し、 残留物にベンゼン 50 m £および 5 %水酸化ナ ト リ ゥム水溶液 30 m £を加えて抽出した。 ベ ンゼン層を水洗し、 無水硫酸マグネ シウ ムで乾燥後減圧 濃縮し、 5 — 〔 4 一 (フエノ キ シ) フエ二ルチオ〕 — 1, 2, 4 —チアジアゾ―ル 4.0g (14ミ ルモル、 収率 94% ) を 得た。 得られた化合物 4.0g (14ミ ルモル) にク ロ口ホル ム 50 m £および 70%メ タク口ル過安息香酸 9. lg (37ミル モル) を加え加熱して 4時間還流した。 反応物を氷冷し 5 %水酸化ナ ト リ ウム 100 m £を加えて攪拌後分液しク ロ ロ ホルム層は水洗後、 無水硫酸マグネ シウ ム乾燥し、 ついで減圧下にク ロロホルムを留去した。 得られた粗晶 を n -へキサ ン — トルェ'ン (6 : 1 ol)より再結晶して 5 一 ( '4 一 フエノ キ シベンゼ ンスルホニル) 一 1 , 2 , 4 —チ アジアゾール 3.0g (収率 67%) を得た。 融点 87— 89 'c、 H1 - MR (100 MHz、 CDC 3) ; 57.2 〜 8.4ppm (m、 9After cooling 20 m of ethanol with ice and stirring, add 28% sodium chloride liquid methanol solution 2.9 g (15 min monole), 41 g (phenoxy) thiol nor 3.0 g (14.8 mi) 2.5 g (15 mmol) of 5-bromo-1,2, -thiadiazole and kept under ice-cooling for 30 minutes, then kept at 50'c for 2 hours The reaction product was concentrated to dryness, and the residue was extracted by adding 50 mL of benzene and 30 mL of a 5% aqueous sodium hydroxide solution. The benzene layer was washed with water, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and 5-[4-1 (phenoxy) phenylthio]-1,2, 4-thiadiazole 4.0 g (14 mmol, Yield 94%). To 4.0 g (14 mmol) of the obtained compound was added 50 mL of a form of black mouth and 9.lg (37 mmol) of 70% methanol perbenzoic acid, and the mixture was heated and refluxed for 4 hours. The reaction was cooled on ice, 100 ml of 5% sodium hydroxide was added, and the mixture was stirred and separated.The chloroform layer was washed with water, dried over anhydrous magnesium sulfate, and distilled under reduced pressure to remove chloroform. I left. The obtained crude crystals were recrystallized from n-hexane-toluene (6: 1 ol) to give 51 g ('41 phenoxybenzensulfonyl) -11,2,4-thiadiazole 3.0 g (67% yield). Mp 87- 89 'c, H 1 - MR (100 MHz, CDC 3); 57.2 ~ 8.4ppm (m, 9
H) 、 9.0ppm (s、 1H) 、 Mass; m/e 318 ( M+ ) 実施例 2 化合物番号 91 H), 9.0 ppm (s, 1H), Mass; m / e 318 (M +) Example 2 Compound No. 91
Figure imgf000011_0001
CH
Figure imgf000012_0001
Figure imgf000011_0001
CH
Figure imgf000012_0001
28%ナ ト リ ウ ムメ チラ 一 ト メ タ ノ一ル液 2.9g (15ミ リ モル) とエタノ ール 30 m を混合し、 これに 4 — 〔 4 一 ( ト リ フ ロルメ チル) フエノ キ シ〕 ベンゼンチオール 4. 05 g ( 15ミ リ モル) を加えて攪拌し、 室温でこれに 5 — ク ロノレー 3 ー メ チル一 1 , 2 , 4 ーチア ジアゾール 2.0g (15 ミ リ モル) を加えた。 発熱がやんでから加温して 50 °cに 1時間保った。 反応物を減圧濃縮し、 残留物に水および ベンゼンを加えて抽出し、 ベンゼン層を 10%水酸化ナ ト リ ウムおよび水で洗い、 無水硫驟 グネシゥムで乾燥後 減圧濃縮して、 3 —メ チル一 5 — 〔 4 — ( 4 一 ト リ フル ォ ロ メ チルフエノ キ シ) フエ二ルチオ〕 — 1,2, 4 —チア ジァゾール 4.9gを得た。 この化合物 3.5g ( 9.5ミ ルモ ル) をク ロ ロホルム 30 m & に溶解し、' 攪拌下これにメ タ ク ロル過安息香酸 5. lg (純度 80%、 23.8ミ ルモル) を加 え、 室温で 1時間、 ついで加温して還流下に 4時間保つ た。 反応物を冷却し、 これに氷 20 gおよび 10%水酸化ナ ト リ ウ ム水溶液 20 m ί ( 50ミ ルモル) を加え振とう、 抽 出した。 ク ロ口ホルム層を分取しこれを冷水で 2回洗浄 し、 無水硫酸マグネシゥムで乾燥し、 減圧でク ロ口ホル ムを留去した。 3 —ダチルー 5 — 〔 4 — ( 4 一 ト リ フル ォ ロ メ チルフエノ キ シ) ベンゼンスルホニル〕 一 1,2, 4 — チアジアゾールの結晶 3.8 gを得た。 これをシク ロへキ サ ンから再結晶して精製品を得た。 融点 80.5 - 81.5で 、 TLC; シ リ カゲル—ベンゼ ン単一スボ ッ ト、 H 1 — NMR; 5 2 Mix 2.9 g (15 mmol) of 28% sodium hydroxide solution with 30 m of ethanol, and add 4-[4-1 (trifluormethyl) phenol B) 4.05 g (15 mmol) of benzenethiol was added and stirred, and at room temperature, 2.0 g (15 mmol) of 5—Clonole 3-methyl-1,1,2-, 4-thiadiazole was added. Was. After the exotherm ceased, the mixture was heated and kept at 50 ° C for 1 hour. The reaction product was concentrated under reduced pressure, water and benzene were added to the residue, and the mixture was extracted. The benzene layer was washed with 10% sodium hydroxide and water, dried over anhydrous sulfuric acid, and concentrated under reduced pressure. Chill-1 5-[4-(4-Trifluoromethylphenoxy) phenylthio]-1,2,4-thiadiazole 4.9 g was obtained. Dissolve 3.5 g (9.5 mmol) of this compound in 30 m of chloroform and add 5. lg (purity 80%, 23.8 mmol) of metachloroperbenzoic acid to the mixture under stirring. For 1 hour and then heated and maintained under reflux for 4 hours. The reaction product was cooled, added with 20 g of ice and 20 mL (50 mmol) of a 10% aqueous sodium hydroxide solution, and extracted by shaking. The black hole form layer was separated, washed twice with cold water, dried over anhydrous magnesium sulfate, and the black hole form was distilled off under reduced pressure. 3 — Dachiru 5 — [4 — (4-Trifluoromethyl benzene) benzenesulfonyl] 1, 1, 2, 4 — 3.8 g of thiadiazole crystals were obtained. This was recrystallized from cyclohexane to obtain a purified product. Melting point 80.5-81.5, TLC; silica gel-benzene single spot, H 1 —NMR; 52
7ppm (sヽ 3H) 、 7·2〜 8.3ppm (m. 8H) 7ppm (s ヽ 3H), 7.2-8.3ppm (m.8H)
実施例 3 化合物番号 93 Example 3 Compound No. 93
S03NaS0 3 Na
Figure imgf000013_0001
Figure imgf000013_0001
実施例 1 で得られた化合物 7.0g (22ミ リ モル) を 1, 2 ー ジク ロルヱタ ン 30 m に溶解し、 攪拌下に 0 'Cでこれ に 25%発煙硫酸 7gを L0分間に加えた。 氷冷 に 1時間保 つた後加温して 15'cに 1時間保つた。 減圧下で 1, 2 -ジ ク ロルエタ ンを留去した後得られたタール状物に氷 40 g を加え攪拌し、 濾過して透明水溶液を得た。 これを氷冷 し 20%水酸化ナ ト リ ゥ ム水溶液で中和した。 ナ ト リ ゥ ム 塩の結晶が折出した。 結晶を濾別し、 飽和食塩水で洗浄 し、 ついでァセ ト ン洗浄し、 減圧下 乾燥して無色粉状 の 4 — C 4 - (1, 2, 4 —チア ジアゾールー 5 — ィ ル) ス ルホニル〕 フエ ノ キ シベ ンゼ ンスルホ ン酸ナ ト リ ゥ ム 7. 16 gを得た。 分解点 260 'c以上。 収率 77.5%。 実施例 4 化合物番号 94 7.0 g (22 mmol) of the compound obtained in Example 1 was dissolved in 30 m of 1,2-dichloropentane, and 7 g of 25% fuming sulfuric acid was added thereto at 0 ° C with stirring for 0 min. . It was kept on ice for 1 hour, then heated and kept at 15'c for 1 hour. After distilling off 1,2-dichloroethane under reduced pressure, 40 g of ice was added to the obtained tar-like substance, followed by stirring and filtration to obtain a clear aqueous solution. This was cooled on ice and neutralized with a 20% aqueous sodium hydroxide solution. Crystals of sodium salt were deposited. The crystals are separated by filtration, washed with a saturated saline solution, then washed with acetate, dried under reduced pressure, and dried under reduced pressure to give a colorless powder of 4—C 4-(1,2,4-thiadiazole-5-yl) sulfur Ruphonyl] phenoxybenzensulfonate sodium (7.16 g) was obtained. Decomposition point 260 'c or higher. Yield 77.5%. Example 4 Compound No. 94
Figure imgf000014_0001
Figure imgf000014_0001
実施例 3で得られた化合物 4.2g (10ミ リモル) にォキ シ塩化リ ン 4 gを加え 75'cに加温して 1時間 30分保つた, 過剰のォキシ塩化リ ンを減圧留去した。 残留物にジォキ サ ン 15 gを加えて希釈した。 n —プロビルア ミ ン 3g (50 ミ リ モル) とジォキサ ン 30 gの混合物を氷冷し、 攪拌下 この中へさきの希釈液を徐々に加え.た。 室温下に 1時'間 30分保った後減圧濃縮し、 得られた残留物に水および酢 酸.ェチルを加えて抽出した。 酢酸ェチル層を水洗しつい で無水硫酸マグネ シウ ムで乾燥し、 減圧濃縮し 5 - 〔 4 - 〔 4 — (N— n —プロピルスノレフ ァ モ イ ル) フエノ キ シ〕 ベ ンゼンスルホニル〕 — 1 , 2, 4 ーチアジアゾール 3. To 4.2 g (10 mmol) of the compound obtained in Example 3, 4 g of phosphorus oxychloride was added, and the mixture was heated to 75'c and kept for 1 hour and 30 minutes. I left. The residue was diluted with 15 g of dioxan. A mixture of 3 g (50 mmol) of n-proviramine and 30 g of dioxane was cooled on ice, and the diluted solution was gradually added thereto with stirring. After keeping at room temperature for 1 hour and 30 minutes, the mixture was concentrated under reduced pressure, and the obtained residue was extracted by adding water and ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and concentrated under reduced pressure. 5- (4- [4— (Nn-propylsnorefhamayl) phenoxy] benzenesulfonyl] — 1,2,4-thiadiazole 3.
0 gを得た。 これをカラムクロマ トグラフィ ー 〔シリ カ ゲル、 クロ口ホルム -酢酸ェチル(9 : 1)〕 で精製して精 製結晶を得た。 融点 100— 102 'C、 H1 - NMR (100 MHz.0 g was obtained. This was purified by column chromatography [silica gel, silica gel form-ethyl acetate (9: 1)] to obtain purified crystals. H 1 -NMR (100 MHz.
CDC ί 3) ; <5 0.8ppm (t、 3H) 、 1.5pPm(m. 2H) 、 2.9 ppm (t、 210 、 7 〜 8.2ppm (m. 8H) 、 8.7ppm (s 、 1 CDC ί 3); <5 0.8ppm (.. T, 3H), 1.5p P m (m 2H), 2.9 ppm (t, 210, 7 ~ 8.2ppm (m 8H), 8.7ppm (s, 1
H) 、 Mass; m/e 439 ( M + ) 実施例 5 化合物番号 95 H), Mass; m / e 439 (M + ) Example 5 Compound No. 95
Figure imgf000015_0001
Figure imgf000015_0001
氷冷下 61%硝酸 4 g (38.6ミ リ モル) に 97%硫酸 4.4 gを加え、 - 5 でに冷却して攪拌下これに実施例 1 で得 られた化合物 1 2.0 g (6.2ミ リ モル) を加え同温度に 30 分間保った後 25'cに 30分間保った。 反応物に氷および酢 酸ェチルを加えて抽出後分液し、 酢酸ェチル層を水洗し、 無水硫酸マグネシ ムで乾燥後減圧濃縮した。 粗油状物 収量 2.3 g 。 これをカ ラム ク ロ マ ト グラ フ ィ ー 〔シ 力 ゲル、 ベンゼ ン —酢酸ェチル (20 : 1)〕 で精製して 5 - 〔 4 一 ( 4 一 二 ト ロ フエノ キ シ) ベ ンゼ ンスルホニル〕 一 1, 2, 4 —チアジアゾールを得た。 融点 119— 120 °c、 H1 - MR (100 MHz . CDC i 3); δ Ί 〜 8.3PP«I (m、 8Η) 、 8.65ppm (s、 1H) 、 Mass; m/e 363 ( M + ) 4.4 g of 97% sulfuric acid was added to 4 g (38.6 mmol) of 61% nitric acid under ice-cooling, and the mixture was cooled to -5 and stirred, and 12.0 g (6.2 mmol) of the compound obtained in Example 1 was added thereto. ) And kept at the same temperature for 30 minutes and then at 25'c for 30 minutes. Ice and ethyl acetate were added to the reaction product, followed by extraction and liquid separation. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Crude oil yield 2.3 g. This was purified by column chromatography [Shigeru gel, benzene-ethyl acetate (20: 1)], and purified by 5- [4- (4-troenoxy) benzene]. Sulfonyl] 1,2,4-thiadiazole was obtained. Melting point 119-120 ° C, H 1 -MR (100 MHz. CDC i 3 ); δ Ί to 8.3 PP «I (m, 8 Η), 8.65 ppm (s, 1H), Mass; m / e 363 (M + )
実施例 6 化合物番号 11
Figure imgf000015_0002
I 4
Example 6 Compound No. 11
Figure imgf000015_0002
I 4
Figure imgf000016_0001
Figure imgf000016_0001
6 - ( 4 — ク ロノレフエノ キ シ) 一 3 — ピ リ ジ ンチォ一 ル 1.7 g ( 7 ミ リ モル) にエタ ノ ール 30 m および 28 % ナ ト リ ウ ムメ チラ ー ト のメ タ ノ ール溶液 1.42 g (ナ ト リ ゥムメ チラー ト 7 ミ リ モル) を加えて攪拌し、 0 でに冷 却してこれに 5 —ブロム— 1 , 2, 4 —チアジアゾール 1.16 g ( 7 ミ リ モル) を加えた。 25。cに 1時間保った後 50'c に .1時間保った。 '  6- (4—Chronolefoxy) 1 3—Pyridine Chiral 1.7 g (7 mimol) in ethanol 30 m and 28% sodium methylate metabolite Add 1.42 g of sodium chloride solution (7 millimoles of sodium methylate), stir, cool to 0, and add 1.16 g (7 millimoles) of 5-bromo-1,2,4-thiadiazole Was added. twenty five. After holding at c for 1 hour, it was kept at 50'c for .1 hour. '
反応物を減圧下に乾 Iし、 残渣に水およびク ロ口ホル ムを加えて抽出し、 ク 口口ホルム相を水洗しついで無水 硫酸マグネ シウムで乾燥し、 減圧下にク ロロホルムを留 去して 5 — C 6 - ( 4 — ク ロルフエノ キ シ) — 3 — ピ リ ジルチオ〕 — 1 , 2 , 4 —チアジアゾールの油状物 1.8 gを 得た。  The reaction mixture was dried I under reduced pressure, and the residue was extracted by adding water and chloroform.The mouth-form phase was washed with water, dried over anhydrous magnesium sulfate, and chloroform was distilled off under reduced pressure. Then, 5 g of C 6-(4 chlorophenoxy) — 3 —pyridylthio] — 1, 2, 4 — 1.8 g of an oil of thiadiazole was obtained.
5 — 〔 6 — ( 4 一 ク ロルフエノ キ シ) 一 3 — ピ リ ジル チォ〕 一 1 , 2, 4 —チアジアゾール 1 , 8 g (6.2 ミ リモ ル) をク ロ口ホルム 50 m に溶解し、 0 。cに冷却して攪 拌下メ タク ロル過安息香酸 4.6 g (純度 70%、 18.6ミ リ モル) を加え、 25で に 1時間保つた後 40'cに 1時間 30分保 1 δ 5 — [6 — (4-chlorophenoxy) 1-3-pyridylthio] 1, 2, 4 — Thiadiazole 1,8 g (6.2 mimol) is dissolved in 50 m of clog form. 0. Add 4.6 g (purity 70%, 18.6 mmol) of methanol perbenzoic acid with cooling to c and stir, keep at 25 for 1 hour, then keep at 40'c for 1 hour and 30 minutes 1 δ
つた  Ivy
反応物を冷却し水 50 m および 48%水酸化ナ ト リ ゥム 水溶液 2. lgを加えて抽出し、 ク ロ口ホルム層を水洗し、 無水硫酸マグネ シウ ムで乾燥し、 減圧下にク ロ 口 ホルム を留去して 5 — 〔 6 — ( 4 一ク ロルフエノ キ シ) — 3 — ピ リ ジルスルホニル〕 一 1 , 2 , 4 —チアジアゾ一ルの ± .  The reaction mixture was cooled, and 50 g of water and a 48% aqueous sodium hydroxide solution were added for extraction.2 g of the mixture were extracted, and the clot-form layer was washed with water, dried over anhydrous magnesium sulfate, and dried under reduced pressure. (B) After distilling off form, 5 — [6 — (4-chlorophenoxy) — 3 — pyridylsulfonyl] 1, 1, 2, 4 —thiadiazol ±.
a HH a HH
1.6gを得た。 これをベンゼン — n —へキサ ン(1 : 1 vol) から再結晶した。 mp 117 - 119'C Mass; m/e 353 ( M+ ) 実施例 7 化合物番号 138 1.6 g was obtained. This was recrystallized from benzene-n-hexane (1: 1 vol). mp 117-119'C Mass; m / e 353 (M +) Example 7 Compound No. 138
Figure imgf000017_0001
Figure imgf000017_0001
4 ' — メ チルビフエ二ルー 4 — チオ ール l,4 gをエタ ノ 一ル 30 m 中に溶解し一 10 °cに冷却し、 28 %ソ ジゥ ム メ チテ一 ト 1.4gを加えた。 これに 5· -ブロム一 1,2, 4 ― チアジアゾール 1.3gをェタノ ール 10 m に溶かしたもの を滴下した。 滴下終了後 1時間室温で攪拌し、 さらに 10 分間加熱還流した。 エタノ ールを減圧留去し、 残查をシ リ カゲルク ロ マ ト (ベ ンゼン一へキサ ン) で精製し、 5 - ( 4 ' メ チノレビフエ二ルー 4 ー ィ ルチオ) — 1,2, 4 — チアジアゾール 800 rag (収率 40%) を得た。 mp97— 98 °C i 6 1,4 g of 4'-methyl biphenyl 4 -thiol was dissolved in 30 m of ethanol, cooled to 110 ° C, and 1.4 g of 28% sodium methoxide was added. To this was added dropwise 1.3 g of 5-bromo-1,2,4-thiadiazole in 10 m of ethanol. After completion of the dropwise addition, the mixture was stirred at room temperature for 1 hour, and further heated under reflux for 10 minutes. Ethanol was distilled off under reduced pressure, and the residue was purified by silica gel chromatography (benzene-hexane), and 5-(4 'methionolebifueryl 4-dithio) — 1,2,4 — 800 rag of thiadiazole (40% yield). mp97—98 ° C i 6
実施例 8 化合物番号 52 Example 8 Compound No. 52
Figure imgf000018_0001
Figure imgf000018_0001
5 — ( 4 ' ー メ チルビフエ二ルー 4一ィ ルチオ) 一 1, 2 , 4—チアジアゾ一-ノレ 420 ragをク ロ 口 ホルム 30 m に溶 解し、 一 10 'C に冷却した。 これに純度 70%のメ タ ク ロル 過安息香酸 380 を加えた。 そのまま 2時間攪拌した。 その後ざらに室温で 1時間攪拌した。 クロ口ホルム層を 5 %カ セイ ソーダ水溶液で洗い、 無水硫酸マグネ シゥ ム Λ で乾燥後、 クロ口ホルムを留去した。 残查をシ リ カゲル ク ロ マ ト グラ フ ィ ーで精製する こ とによ り 5 — ( 4 ' - メ チルビフエ二ルー 4 ー ィ ルスノレフ ィ ニノレ) — 1,2, 4 — チアジアゾール 300 を得た。 (収率 70%) mp 140 - 141 実施例 9 化合物番号 140  5 — (4'-methyl-biphenyl-41-ylthio) 420 g of 1,1,2,4-thiadiazo-1-nore was dissolved in 30 m of holomade and cooled to 10'C. To this was added 380 of metachloroperbenzoic acid with 70% purity. The mixture was stirred for 2 hours. Thereafter, the mixture was roughly stirred at room temperature for 1 hour. The black mouth form layer was washed with a 5% aqueous solution of sodium hydroxide, dried over anhydrous magnesium sulfate, and the black mouth form was distilled off. The residue was purified by silica gel chromatography to obtain 5 — (4'-methyl biphenyl 2- 4-islunoreffininole) — 1,2,4 — thiadiazole 300 Was. (Yield 70%) mp 140-141 Example 9 Compound No. 140
Figure imgf000018_0002
4—ク ロ ロ ナフタ レ ン 一 1 ー チオール 10.7 gをェタ ノ ール 100 m J2 に溶かし、 0 'C に冷却した。 これに 28 %ソ ジゥムメ チラ一 ト ll gを加えた。 これに 5 —ブロム— 1, 2 , 4—チアジアゾール 9.4 gをエタノ ール 30 m に溶力、 したものを滴下した。 滴下終了後 30分間加熱還流した。 エタノ ールを減圧留去し、 残査をシリ 力ゲルク ロマ トグ ラフィ 一で精製することにより 5 — ( 4 —ク ロロナフチ ルー 1 ー ィ ルチオ) — 1,2, ーチアジアゾ―ル 12 gを得 た。 (収率 78% ) mp 103 - 104 'C
Figure imgf000018_0002
10.7 g of 4-chloronaphthalene-1-thiol was dissolved in 100 mJ2 of ethanol and cooled to 0'C. To this was added llg of 28% sodium methylate. To this, 9.4 g of 5-bromo-1,2,4-thiadiazole dissolved in 30 m of ethanol was dropped. After the completion of the dropwise addition, the mixture was heated under reflux for 30 minutes. Ethanol was distilled off under reduced pressure, and the residue was purified by silica gel chromatography to obtain 12 g of 5- (4-chloronaphthyl 1-dithio) —1,2, -hydroxyazole. . (Yield 78%) mp 103-104 'C
上記実施例を舍め、 同様に製造した本発明化合物の代 表例を第 1表に示す。 Based on the above Examples, Table 1 shows typical examples of the compounds of the present invention produced in the same manner.
Figure imgf000020_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000024_0001
O Z6S/98l〕d/d0/8f0s 9 O Z6S / 98l) d / d0 / 8f0s 9
mm
CM cm
οεマ οε
Figure imgf000026_0001
Figure imgf000026_0001
〕dl/df8/s > Dl / df8 / s>
― ,
Figure imgf000027_0001
3
―,
Figure imgf000027_0001
Three
ΰάdr/s/ s一 ΰάdr / s / s
Figure imgf000028_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000029_0001
Figure imgf000029_0002
Figure imgf000029_0002
§ 8A卜〕ーlddf/8s、 § 8A) -lddf / 8s,
CO CO
Figure imgf000031_0001
Figure imgf000031_0001
Ο Ο
Figure imgf000032_0001
Figure imgf000032_0001
リ dldr/S/ S 9一 Re dldr / S / S 9
m
Figure imgf000033_0001
m
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000035_0001
Co Co
s OM卜s/98〕ldf/d80s/ _ s OM s / 98】 ldf / d80s / _
Bird
Figure imgf000036_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000037_0001
oo t - rHoo t-rH
1 in 1 in
H H
ϋ  ϋ
Figure imgf000038_0001
Figure imgf000038_0002
Figure imgf000038_0001
Figure imgf000038_0002
産業上の利用可能性 : Industrial applicability:
本発明化合物はカ ンジダ症、 ト リ コモナス症、 皮厣糸 状菌症等の病原微生物に対し効力が認められ、 特にカ ン ジダ菌に対しては公知化合物より優れた抗菌力を示し、 かつ皮厣一次刺激性が見られず、 抗真菌剤としての開発 が期待される。  The compounds of the present invention are effective against pathogenic microorganisms such as candidiasis, trichomoniasis, dermatophytosis, etc., and exhibit an antibacterial activity superior to known compounds, particularly against candidiasis, and Skin No primary irritation is expected, and development as an antifungal agent is expected.
本発明化合物の効力及び皮) f一次刺激性に関する若干 の試験例を示す。  Some test examples relating to the efficacy of the compound of the present invention and the primary irritancy of the skin are shown.
試験例 1 Test example 1
被検菌と して ト リ コ フ イ ー ト ン. メ ンタグロフ ィ テス (Trichophyton mentagrophy tes) IFO 6202を使用し、 マ イ ク口プレー トを用いた寒天平板希釈法により抗菌力を 測定し'た。 すなわち、 試験化合物を DMS0に溶解して最終 試験濃度の 100倍液を作製し、 50でに加温したサブロー ブ ドウ糖寒天培地に 1 : 100 の割合に加えよ く攪拌した, そして、 その 1 m をマイ ク ロプレー ト 〔 Fa Icon 3047 Using Trichophyton mentagrophytes IFO 6202 as the test bacterium, the antibacterial activity was measured by the agar plate dilution method using a microplate. Was. That is, the test compound was dissolved in DMS0 to prepare a 100-fold solution of the final test concentration, and the mixture was added to the Sabrobe dextrose agar medium heated at 50 to 1: 100 and stirred well. m to My Plate [Fa Icon 3047
(登録商標) 〕 のゥエル ( 015«) に分注した。 ついで 固化したサブローブ ドゥ糖寒天培地表面に被検菌液の 0. 1 m & (胞子数約 106偭ノ m & ) を添加した後、 27'Cで(Registered trademark)]. Then, after the addition of 0. 1 m of the test bacterial solution and (about 106 spores偭No m &) to solidified Saburobu de sugar agar surface, at 27'C
7 日間培養し、 最小発育阻止濃度 (MIC u g/ m.H ) を求 めた。 結果を第 2表に示す。 •i 合物番 M I C β g/ m &After culturing for 7 days, the minimum inhibitory concentration (MIC ug / mH) was determined. The results are shown in Table 2. • i Compound number MIC β g / m &
11 丄 .25 11 丄 .25
18 0.625 18 0.625
19 0.62519 0.625
25 0.62525 0.625
26 1.25 26 1.25
34 1.25  34 1.25
35 丄 .25  35 丄 .25
36 丄, 25  36 丄, 25
37 0.625 37 0.625
38 1.25 38 1.25
39 1.25  39 1.25
50 0.625 50 0.625
51 0.62551 0.625
52 0.62552 0.625
54 1.25 54 1.25
59 0.625 59 0.625
60 0.62560 0.625
61 - 0.62561-0.625
63 - 1.25 63-1.25
73 0.625 73 0.625
78 1.25 78 1.25
90 0.625 90 0.625
91 1.25 91 1.25
99 1.25 対照化合物 * 0.625  99 1.25 Reference compound * 0.625
* ク ロ ト リ マゾーノレ* Clotory masonole
Figure imgf000040_0001
試験例 2
Figure imgf000040_0001
Test example 2
被検菌と してカ ンジダ アルビカ ンス(Candida albic ans) IFO 0579 を使用し、 マイ ク ロプレー トを用いた寒 天平板希釈法により抗菌力を測定した。 すなわち、 試験 化合物を DMS0に溶解して最終試験濃度の 100倍液を作製 し、 50てに加温したサブローブドウ糖寒天培地に 1: 100 の割合に加えよ く攬拌した。 そして、 その 1 m をマイ ク ロプレー ト 〔Falcon 3047 (登録商標) 〕 のゥエル Using Candida albicans IFO 0579 as a test bacterium, the antibacterial activity was measured by an agar plate dilution method using microplates. That is, the test compound was dissolved in DMS0 to prepare a 100-fold solution of the final test concentration, and the mixture was added to a Sabouraud glucose agar medium heated to 50% in a ratio of 1: 100, and the mixture was stirred well. Then, 1 m of the microplate was used for microplate [Falcon 3047 (registered trademark)].
( Φ 15M ) に分注した。 ついで固化したサブローブ ドウ 糖寒天培地表面に被検菌液の 0.1 m t (菌数約 10ft偭ノ m & ) を添加した後、 27 'cで 7 日間培養し、 最小発育阻 止濃度 · (MIC μ g/ m & ) を求めた。 (Φ15M). Then, after adding 0.1 mt (about 10 ft偭 m &amp;) of the test bacterial solution to the surface of the solidified sublobe dough sugar agar medium, culture the cells at 27'c for 7 days to obtain the minimum inhibitory concentration · (MIC μg / m &) was determined.
結果を第 3表に示す。  Table 3 shows the results.
試験例 3 Test example 3
化合物を Polyethylene glycol 軟膏 (400 60%と 1540 40 % ) に 1 %、 5 10 %の割合に舍ませ、 ニ ュ ージラ ン ド白色ゥサギの剃毛した皮廣に塗布し、 Draze , J.H. (J. pharm. Exp. Therap. 82, 377-390, 1944)の方法 に準拠し一次刺激率(P. I . I . )を求めた。  The compounds were applied to Polyethylene glycol ointment (400 60% and 1540 40%) at 1% and 5 10%, applied to New Zealand white heron shaved skin, Draze, JH (J. pharm. Exp. Therap. 82, 377-390, 1944) to determine the primary stimulus rate (PII).
結果を第 3表に示す。 第 3 表 Table 3 shows the results. Table 3
Figure imgf000042_0003
対照化合物 1 *
Figure imgf000042_0003
Control compound 1 *
C & (特公昭 37*— 17997)
Figure imgf000042_0001
C & (* 37 * -17997)
Figure imgf000042_0001
対照化合物 2  Control compound 2
CF3 (特開昭 56 - 61370)
Figure imgf000042_0002
CF 3 (JP 56-61370)
Figure imgf000042_0002

Claims

請 求 の 範 囲 The scope of the claims
l . 一般式 (0) n 一 Al. General formula (0) n A
Figure imgf000043_0001
Figure imgf000043_0001
{式中、 Rは水素原子、 ハロゲン原子、 (^〜 4 アルキ ル基、 ト リ フノレオ ロ メ チノレ基、 フ エ ニル基又は 〜4 ァ o† {Wherein, R represents a hydrogen atom, a halogen atom, (^ - 4 alkyl group, Application Benefits Funoreo ii main Chinore group, full et alkenyl group or 1-4 § o †
ルコキシ基を、 The alkoxy group is
nは、 0 、 1又は 2を、  n is 0, 1 or 2,
Aは、 式 , Q で表される基、 A is a group represented by the formula and Q,
式 - 式 Expression-Expression
Figure imgf000043_0002
,
Figure imgf000043_0002
〔式中、 Xはハロゲン原子又はハ ロゲン原子で置換され ていてもよい 〜 4 アルキル基を、 Wherein, X is a halogen atom or a C androgenic ~ which may be substituted with atoms 4 alkyl group,
mは、 0 、 1又は 2を、  m is 0, 1 or 2,
Bは、 CH、 N又は Nを、 B represents CH, N or N,
Wは、 一 0——、 一 N—、 W is one 0——, one N—,
k k
4.2 4.2
r6 r8 0 r 6 r 8 0
0 ■ Cチ 又は N— C— を、 r7 0 ■ C Chi or N-C-a, r 7
〔式中、 r3、 r4、 r5、 r6 r7及び r8はそれぞれ水素原 子、 ヒ ドロキシ基又は 〜 アルキル基を k及び j はそ れぞれ 1、 2又は 3を示す ) (In the formula, r 3 , r 4 , r 5 , r 6 r 7 and r 8 each represent a hydrogen atom, a hydroxy group or an alkyl group, and k and j each represent 1, 2 or 3, respectively.)
£ は 0又は 1 を、  £ is 0 or 1,
(r9) i (r 9 ) i
Qは式 で表される基、
Figure imgf000044_0001
Q is a group represented by the formula:
Figure imgf000044_0001
(式中、 Gは CH、 N又は Nを、  (Where G is CH, N or N,
r 9はハロゲン原子で置換されていても'よい C t4 ア クレキ クレ基、 ァノレコ キ シ基、 r 9 is optionally substituted with a halogen atom 'good C t ~ 4 A Crequi Kure group, Anoreko key sheet group,
_ I 0  _ I 0
式 S02N' < (r10 及び r1 1 はそれぞれ水素 Formula S0 2 N '<(r 10 and r 11 are each hydrogen
r 1 I 原子又は 〜 4 アルキル基を'示す。 ) で表され る基、 式一 S03f1 (M : アルカ リ金属) で表され る基、 ハロゲン原子又はニ ト ロ基を、 i は 0、 1 又は 2を示す。 ) 式 で表される基、r represents a 1 I atom or a 44 alkyl group. ) In represented Ru group, wherein one S0 3 f1 (M: alkali metal) in represented Ru group, a halogen atom or a double filtrated group, i is represents 0, 1 or 2. ) A group represented by the formula:
Figure imgf000044_0002
式 H"C厂 (pH2)h で表される基、
Figure imgf000044_0002
A group represented by the formula H "C factory (pH 2 ) h,
(式 Φ、 hは 3、 4又は 5を示す。 )  (Equation Φ, h indicates 3, 4 or 5.)
C3-8シク 口アルキル基又は 式 で表される基を、
Figure imgf000045_0001
C 3 - 8 consequent opening alkyl or A group represented by the formula
Figure imgf000045_0001
(式中、 B、 n及び Rは前記と同じ意味を示す。 )  (In the formula, B, n and R have the same meanings as described above.)
0  0
ΐ  ΐ
Ε及び Dはそれぞれ C H、 N又は Nを、 (但し、 E及  Ε and D represent CH, N or N, respectively (however, E and
0  0
 †
び Dは同時に N又は Nではない。 ) And D are not N or N at the same time. )
r1及び r2はそれぞれ水素原子、 ハロゲン原子又は Ct〜 * アルキル基を Yは、 0、 CH2 、 S又は S02 を示す。 但し、 Yを含む 3環系において 1 と 2及び 3 と 4 との間 の はそれぞれ 1重結合又は 2重結合を示す。 〕 } で表 される化合物。 r 1 and r 2 are each a hydrogen atom, a halogen atom or a C t ~ * alkyl group Y represents a 0, CH 2, S or S0 2. However, between 1 and 2 and between 3 and 4 in the three-ring system containing Y represents a single bond or a double bond, respectively. ]] The compound represented by these.
2. 一般式 al2. General formula al
Figure imgf000045_0002
Figure imgf000045_0002
( 式中、 Rは水素原子、 ハロゲン原子、 C,〜4 アルキ ル基、 ト リ フルォロメ チル基、 フエニル基又は C,〜4 ァ ルコキシ基を、 Hal はハロゲン原子を示す。 ) で表され る化合物と (Wherein, R represents a hydrogen atom, a halogen atom, C, ~ 4 alkyl group, Application Benefits Furuorome butyl group, phenyl group or C, and 1-4 § alkoxy group, Hal represents a halogen atom.) It expresses in Compound
一般式  General formula
HS(0)n ' 一 A  HS (0) n 'one A
(式中、 n ' は 0又は 2 を、 Aは、 式 Q で表される基 式 で表される基、 又は 式 で表される基を、
Figure imgf000046_0001
(Where n 'is 0 or 2, A represents a group represented by the formula represented by the formula Q, or a group represented by the formula:
Figure imgf000046_0001
〔式中、 Xは、 ハロゲン原子又はハロゲン原子で置換さ れていてもよい 〜4 アルキル基を、 Wherein, X is a halogen atom or a halogen atom may be substituted with 1-4 alkyl groups,
Hiは、 0、 1 又は 2を、
Figure imgf000046_0002
Hi is 0, 1 or 2;
Figure imgf000046_0002
Bは、 CH、 N又は Nを、  B represents CH, N or N,
0  0
Wは、 一 0—、 — ~~ ( C ) - 一  W is one 0—, — ~~ (C)-one
k r 8 O kr 8 O
O—— f C )—— 又は 一 N— C一 を、  O—— f C) —— or one N—C
〔式中、 r 3、 r 4、 r 5、 r 6、 r 7及び r 8はそれぞれ水素原 子、 ヒ ドロキシ基又は 〜4 アルキル基を k及び j はそ れぞれ 1、 2又は 3を示す。 ) (In the formula, r 3 , r 4 , r 5 , r 6 , r 7 and r 8 each represent a hydrogen atom, a hydroxy group or a 〜4 alkyl group, and k and j each represent 1, 2 or 3 respectively. Show. )
は 0又は 1 を、  Represents 0 or 1,
Qは式 で表される基、Q is a group represented by the formula:
Figure imgf000046_0003
0
Figure imgf000046_0003
0
 †
(式中、 Gは CH、 N又は Nを  (Where G is CH, N or N
r9はハロゲン原子で置換されていてもよい r 9 may be substituted with a halogen atom
アルキル基、 アルコ キ シ甚、  Alkyl group, alcohol,
1 0  Ten
式 S02N < (r10 及び r11 はそれぞれ水素 r11 Formula S0 2 N <(r 10 and r 11 are each hydrogen r 11
原子又は (^〜4 アルキル基を示す。 ) で表され る基、 式一 S03M (M : アルカ リ金属) で表され る基、 ハロゲン原子又はニ ト ロ基を、 Atom or (^ 1-4 alkyl group shown.) In the depicted Ru group, wherein one S0 3 M: group you express by (M alkali metal), a halogen atom or a double filtrated group,
i は 0、 1又は 2を示す。 ) 式 " 0丄〇] で表される基、  i represents 0, 1 or 2. ) A group represented by the formula "0 丄 〇]
Λ  Λ
式 ((^H2)h で表される基、 (式中、 hは 3'、 4又は 5を示す。 ) A group represented by the formula ((^ H 2 ) h, wherein h represents 3 ′, 4 or 5)
C 38シク 口 アルキル基又は C 3 - 8 consequent opening alkyl or
式 で表される基を、
Figure imgf000047_0001
A group represented by the formula
Figure imgf000047_0001
(式中、 B、 n及び Rは前記と同じ意味を示す。 )  (In the formula, B, n and R have the same meanings as described above.)
0  0
 †
E及び Dはそれぞれ C H、 N又は Nを、 (但し、 E及  E and D represent CH, N or N, respectively (however, E and D
0  0
T  T
び Dは同時に N又は Nではない。 ) r1及び rzはそれぞれ水素原子、 ハロゲン原子又は C,〜, アルキル基を Υは、 0、 CH2 、 S又は SO 2 を示す。 And D are not N or N at the same time. ) r 1 and r z each represent a hydrogen atom, a halogen atom or a C,-, alkyl group; and Υ represents 0, CH 2 , S or SO 2 .
但し、 Yを舍む 3環系において 1 と 2及び 3 と 4 との間 の はそれぞれ 1重結合又は 2重結合を示す。 〕 } .で表 される化合物とを塩基の存在下で反応させることを特徴 とする一般式 (0)n ' 一 A C I )However, between 1 and 2 and between 3 and 4 in the three-ring system containing Y represent a single bond or a double bond, respectively. The compound represented by the general formula (0) n'-ACI) characterized by reacting a compound represented by the formula (1) in the presence of a base:
Figure imgf000048_0001
Figure imgf000048_0001
(式中、 R、 n '及び Aは前記と同じ意味を示す。 ) で表される化合物の製造方法。  (Wherein, R, n ′ and A have the same meanings as described above.)
PCT/JP1985/000617 1984-11-08 1985-11-06 1,2,4-thiadiazole derivatives WO1986002927A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP59/234215 1984-11-08
JP23421584 1984-11-08

Publications (1)

Publication Number Publication Date
WO1986002927A1 true WO1986002927A1 (en) 1986-05-22

Family

ID=16967496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1985/000617 WO1986002927A1 (en) 1984-11-08 1985-11-06 1,2,4-thiadiazole derivatives

Country Status (2)

Country Link
AU (1) AU5067985A (en)
WO (1) WO1986002927A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095205A1 (en) * 2005-03-09 2006-09-14 Merck Sharp & Dohme Limited Heteroarylsulfonyl stilbenes as 5-ht2a antagonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623328B2 (en) * 1987-03-09 1994-03-30 ポリプラスチックス株式会社 Wire covering material

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5661370A (en) * 1979-10-26 1981-05-26 Nippon Soda Co Ltd 1,2,4-thiadiazole derivative, its preparation and agricultural and horticultural and medical germicide
DD222770A1 (en) * 1984-03-14 1985-05-29 Bitterfeld Chemie FUNGICIDAL AGENTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5661370A (en) * 1979-10-26 1981-05-26 Nippon Soda Co Ltd 1,2,4-thiadiazole derivative, its preparation and agricultural and horticultural and medical germicide
DD222770A1 (en) * 1984-03-14 1985-05-29 Bitterfeld Chemie FUNGICIDAL AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 99(17):139863w (1983), (Columbus, USA), "Production of Etridiazole and Its Analogs". *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095205A1 (en) * 2005-03-09 2006-09-14 Merck Sharp & Dohme Limited Heteroarylsulfonyl stilbenes as 5-ht2a antagonists

Also Published As

Publication number Publication date
AU5067985A (en) 1986-06-03

Similar Documents

Publication Publication Date Title
EP0202164B1 (en) (benzoyl-4-piperidino)-2-phenyl-1-alkanol derivatives, their preparation and their use as medicines
JPS6089474A (en) Morphinan derivative, production thereof and antitumor agent containing said compound
EP0379441A1 (en) Benzopyrane derivatives, their preparation and pharmaceutical compositions containing them
EP0350403A1 (en) (Aza)naphthalenesultam derivatives, process for their preparation and drugs containing same
EP0433149A2 (en) Serotonin antagonists, their preparation and pharmaceuticals containing them
CH635080A5 (en) SUBSTITUTED PYRAZOLES IN POSITION 4, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2561647A1 (en) 1- (HYDROXYMETHYL) -1,6,7,11B-TETRAHYDRO-2H, 4H- (1,3) -OXAZINO- OR -THIAZINO (4,3, A) ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING
JP3030780B2 (en) Optically active ketene dithioacetal derivative and method for producing the same
EP0406112B1 (en) 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity
EP0374041B1 (en) Medicaments containing 2-benzothiazolamine derivatives, compounds and their preparation
EP1960387A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
EP0006789A1 (en) Bis(aryloxy-alcanecarboxylic compounds, their preparation and their therapeutic use
EP1032569A1 (en) Imidazole derivatives, preparation and therapeutic application thereof
WO1986002927A1 (en) 1,2,4-thiadiazole derivatives
US4367338A (en) Urazole analogs of prostaglandins
EP0303348B1 (en) 2-amino-5-hydroxy-4-pyrimidones
BE779775A (en) DERIVATIVES OF UREA, METHOD FOR PREPARING THEM AND THEIR APPLICATIONS
NO743980L (en)
EP0090275B1 (en) Isoxazole (5,4-b) pyridines
HU229135B1 (en) Benzofurane derivatives
EP0141686A1 (en) Indole derivatives, their preparation and their therapeutical application
WO1999031097A1 (en) Imidazol derivatives as muscarinic m3 receptor antagonists
KR950014792B1 (en) Benzimidazole derivatives and process for their preparations
JPH07215952A (en) Catechol derivative
EP0217376B1 (en) Process for preparing optically active alpha-haloalkyl-arylketones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK FI JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE